IL37235A - Pharmaceutical compositions containing (2-thiazolyl)thiourea derivatives - Google Patents
Pharmaceutical compositions containing (2-thiazolyl)thiourea derivativesInfo
- Publication number
- IL37235A IL37235A IL37235A IL3723571A IL37235A IL 37235 A IL37235 A IL 37235A IL 37235 A IL37235 A IL 37235A IL 3723571 A IL3723571 A IL 3723571A IL 37235 A IL37235 A IL 37235A
- Authority
- IL
- Israel
- Prior art keywords
- thiazolyl
- thiourea
- active ingredient
- essential active
- methyl
- Prior art date
Links
- LOCOYCNSPKQNRY-UHFFFAOYSA-N 1,3-thiazol-2-ylthiourea Chemical class NC(=S)NC1=NC=CS1 LOCOYCNSPKQNRY-UHFFFAOYSA-N 0.000 title description 2
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 239000004480 active ingredient Substances 0.000 claims description 20
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 4
- 230000000078 anti-malarial effect Effects 0.000 claims description 4
- 230000036772 blood pressure Effects 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- FIGRRRXEUUOHRS-UHFFFAOYSA-N 1,1-dimethyl-3-(4-methyl-1,3-thiazol-2-yl)thiourea Chemical compound CN(C)C(=S)NC1=NC(C)=CS1 FIGRRRXEUUOHRS-UHFFFAOYSA-N 0.000 claims 1
- 238000013329 compounding Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000003430 antimalarial agent Substances 0.000 description 2
- 229940033495 antimalarials Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VQTRGMDNNYNBNG-UHFFFAOYSA-N 1,1-diethyl-3-(1,3-thiazol-2-yl)thiourea Chemical compound CCN(CC)C(=S)NC1=NC=CS1 VQTRGMDNNYNBNG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1124070 | 1970-07-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL37235A0 IL37235A0 (en) | 1971-10-20 |
| IL37235A true IL37235A (en) | 1973-10-25 |
Family
ID=4371509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL37235A IL37235A (en) | 1970-07-24 | 1971-07-05 | Pharmaceutical compositions containing (2-thiazolyl)thiourea derivatives |
Country Status (8)
| Country | Link |
|---|---|
| AU (1) | AU3041671A (enrdf_load_stackoverflow) |
| BE (1) | BE770403A (enrdf_load_stackoverflow) |
| DE (1) | DE2137045A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2100948B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1330545A (enrdf_load_stackoverflow) |
| IL (1) | IL37235A (enrdf_load_stackoverflow) |
| NL (1) | NL7108189A (enrdf_load_stackoverflow) |
| ZA (1) | ZA714076B (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5593993A (en) * | 1991-08-02 | 1997-01-14 | Medivir Ab | Method for inhibition of HIV related viruses |
| IL102548A (en) * | 1991-08-02 | 1998-08-16 | Medivir Ab | Thiourea derivatives for use in the preparation of medicaments for the inhibition of hiv and the treatment of aids and some such novel compounds |
-
1971
- 1971-06-15 NL NL7108189A patent/NL7108189A/xx unknown
- 1971-06-22 ZA ZA714076A patent/ZA714076B/xx unknown
- 1971-06-24 AU AU30416/71A patent/AU3041671A/en not_active Expired
- 1971-07-05 IL IL37235A patent/IL37235A/en unknown
- 1971-07-22 FR FR7126840A patent/FR2100948B1/fr not_active Expired
- 1971-07-23 GB GB3475871A patent/GB1330545A/en not_active Expired
- 1971-07-23 BE BE770403A patent/BE770403A/xx unknown
- 1971-07-23 DE DE19712137045 patent/DE2137045A1/de active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB1330545A (en) | 1973-09-19 |
| FR2100948A1 (enrdf_load_stackoverflow) | 1972-03-24 |
| IL37235A0 (en) | 1971-10-20 |
| AU3041671A (en) | 1973-01-04 |
| BE770403A (fr) | 1972-01-24 |
| FR2100948B1 (enrdf_load_stackoverflow) | 1974-09-06 |
| DE2137045A1 (de) | 1972-01-27 |
| NL7108189A (enrdf_load_stackoverflow) | 1972-01-26 |
| ZA714076B (en) | 1972-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1043610C (zh) | 新的治疗剂 | |
| EP1315505B1 (en) | Pharmaceutical compositions for headache, migraine, nausea and emesis | |
| DE3586920T2 (de) | Benzopyranverbindungen zur verwendung auf das kardiovaskulaere system. | |
| US4804669A (en) | Treatment of pain with a piperidine | |
| US5055457A (en) | Pharmaceutical combinations product and the preparation and use thereof | |
| UA81003C2 (en) | Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450 | |
| EP0629400A1 (en) | Idebenone compositions for treating Alzheimer's disease | |
| IL37235A (en) | Pharmaceutical compositions containing (2-thiazolyl)thiourea derivatives | |
| JPH0352815A (ja) | 血管内血液凝固症候群の治療剤 | |
| JP3322311B2 (ja) | 脳性マラリアに抗する作用を有するアイロプロスト | |
| JPH03109324A (ja) | 血管新生阻害剤 | |
| US4666889A (en) | Method for combatting viral infections | |
| KR101349752B1 (ko) | 정족수 감지 억제 활성 및 항균 활성을 갖는 항균용 조성물 | |
| KR101588949B1 (ko) | 플루나리진을 유효성분으로 함유하는 뇌암에 대한 항암 활성 보조제 | |
| KR950007101B1 (ko) | 소화성 궤양 치료제 | |
| EA022711B1 (ru) | Комбинация дибромида 1,12-додекаметилен-бис-[4-метил-5-(2-гидроксиэтил)тиазолия] и артесуната для лечения тяжелой формы малярии | |
| US4892876A (en) | Method for inhibiting HIV and an pharmaceutical composition therefor | |
| US3767804A (en) | Method of combatting malaria | |
| US3852454A (en) | Treatment of rheumatoid arthritis | |
| KR970003049B1 (ko) | 혈소판감소증 예방 및 치료제 | |
| EP0830862A1 (en) | Anti-hiv drugs | |
| EP0163258A2 (en) | New use of dihydroergotamine | |
| JPH0212932B2 (enrdf_load_stackoverflow) | ||
| EP0729950A1 (en) | Anti-hiv drug | |
| EP1155694A1 (en) | Anti-hiv infection agents and method for treating hiv infection |